As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

More Hong Kong patients suffering from spinal muscular atrophy (SMA) will be able to enjoy a government subsidy to control ...

A group of questionnaires called PROfuture can meaningfully measure a variety of symptoms of SMA that impact patients, a study reported.

Biogen said that new data examining of its already approved spinal muscular atrophy treatment Spinraza (nusinersen) indicates ...

The court said Switzerland’s refusal to pay for Spinraza for a quadriplegic patient with spinal muscular atrophy did not ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save ...